Vigil® is a novel late stage immunotherapy [44,45,46] utilizing GMCSF-wt-bi-shRNA-furin plasmid transfected autologous tumor tissue designed to deliver personalized clonal neoantigen targets, thereby expanding CD8+ T cell clonal neoantigen-targeting effector cells within the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.